PURE Bioscience reports revenues for fiscal quarter ended October 31, 2009

PURE Bioscience (NASDAQ:PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today reported revenues for the fiscal quarter ended October 31, 2009 of $221,900 compared with revenues of $110,600 in the same quarter of the prior fiscal year. The Company reported a net loss of $(1,711,200), or $(0.05) per share, for the current quarter compared with a loss of $(1,605,300), or $(0.05) per share, in the first fiscal quarter last year.

Michael L. Krall, President and CEO of PURE Bioscience, stated, “Several key events during the quarter substantially accelerated the momentum of our business development activities. Obtaining the U.S. EPA registration of our SDC-based sanitizer for food contact surfaces and equipment, the result of six years of work with the EPA, has opened tremendous market opportunities for us in farms, food processing plants, schools, hospitals, restaurants and homes. Our team is positioned to rapidly penetrate these major new markets for PURE following the issuance of federal and state registrations of our disinfectant to include the new food surface contact sanitizer claims. Those registrations are expected to be completed in the first half of 2010. This milestone with the EPA also supports our ongoing pursuit, through USDA and FDA, of direct food contact applications of SDC-based formulations as an antimicrobial food processing aid.”

Krall continued, “In mid-October, we initiated an aggressive and proactive new business strategy by signing Richmont Sciences to lead PURE’s direct sales and marketing efforts for our existing SDC-based disinfectant. As part of its initial marketing efforts, John Rochon and his team have already held meetings with many potential new customers and have created a heightened awareness of SDC-based disinfectant products on a national level in multiple markets in anticipation of the registration of the IV-7 Ultimate Germ Defense™ product and their subsequent full-scale sales launch. Richmont’s commitment, energy, passion and invaluable expertise is coinciding with a recent and rising urgency in the marketplace for a responsible and effective weapon against the ever increasing threat of dangerous pathogens in our everyday lives. State registrations for IV-7 should be finalized within the next 90 days, and we expect Richmont to hit the ground running. Richmont will also market the disinfectant/food contact sanitizer product when it becomes available.

“Existing distributors of SDC-based hard surface disinfectant are also gaining traction in their respective markets. Yesterday, BioTech Medical launched its public health information website, www.touchsurfaces.org. Dr. Bob Arnot, physician and popular television medical correspondent, serves as the chief medical educator for the campaign, which recommends BioTech’s SDC product, SpectraSan 24^TM hard surface disinfectant, as a powerful weapon in eradicating H1N1, MRSA, VRE, Norovirus and other dangerous pathogens commonly spread on hard surfaces.”

Krall concluded, “Our medical and pharmaceutical projects are also building momentum as FTA works with leading researchers and hospitals, including its partner, Cleveland Clinic, to establish and conduct trials for a diverse set of SDC-based products. We anticipate announcing clinical progress in the coming quarters.”